News

Astellas Pharma announces FDA approval of XOSPATA.

Posted on 11.30.2018

Astellas Pharma US, Inc. is pleased to announce that the FDA has approved XOSPATA. XOSPATA is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation … Read More

(FDA) approves a label change for ADCETRIS® (brentuximab vedotin) for injection, for intravenous use.

Posted on 11.19.2018

On November 16, 2018, the U.S. Food and Drug Administration (FDA) approved a label change for ADCETRIS® (brentuximab vedotin) for injection, for intravenous use.

The new indication is as follows:

  • Adult patients with previously untreated systemic anaplastic large cell lymphoma
Read More

IMFINZI® (durvalumab) injection has been assigned a unique HCPCS code by the Centers for Medicare & Medicaid Services (CMS).

Posted on 11.16.2018

AstraZeneca is pleased to announce that IMFINZI® (durvalumab) injection has been assigned a unique HCPCS code by the Centers for Medicare & Medicaid Services (CMS).

Effective for dates of services on or after January 1, 2019, the following code can … Read More

FDA-Approved Indication for KEYTRUDA® (pembrolizumab) for the Treatment of Adult Patients With Hepatocellular Carcinoma (HCC)

Posted on 11.16.2018
Merck is pleased to announce that KEYTRUDA has been approved by the FDA for the treatment of patients with HCC who have been previously treated with sorafenib. This indication is approved under accelerated approval based on tumor response rate and
Read More

FDA-Approved Indication for KEYTRUDA® (pembrolizumab) Announced

Posted on 11.9.2018

 

Merck is pleased to announce that KEYTRUDA in combination with carboplatin and either paclitaxel or nab-paclitaxel has been approved by the FDA for the first-line treatment of patients with metastatic squamous NSCLC.

KEYTRUDA is also indicated in combination with

Read More

U.S. FDA Approves LORBRENA® (lorlatinib) for Previously-Treated ALK-Positive Metastatic NSCLC

Posted on 11.5.2018

Pfizer Inc. (NYSE:PFE) announced 11-5-18 that the U.S. Food and Drug Administration (FDA) has approved LORBRENA® [lor-BREN-ah] (lorlatinib), a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) whose disease … Read More

CMS releases the final rule for the Medicare Physician Fee Schedule Changes for 2019.

Posted on 11.3.2018

The Centers for Medicare & Medicaid Services (CMS) released the final rule for the Medicare Physician Fee Schedule (MPFS) and Quality Payment Program (QPP) outlining reimbursement changes for 2019. CMS estimates that the overall impact will be a one percent … Read More

Pfizer announced the FDA approval of TALZENNA® (talazoparib) on October 16, 2018.

Posted on 11.1.2018

Pfizer announced the FDA approval of TALZENNA® (talazoparib) on October 16, 2018. The following information is for your review:

Prescribing Information: click hereRead More

American Society of Clinical Oncology to submit comments on Part B Payment Model Proposal

Posted on 11.1.2018

ASCO shares the Administration’s goal of achieving lower drug costs but is concerned about some aspects of the proposal. ASCO is analyzing the proposal to determine the impact on patient care and practices. The society will respond to the Administration’s … Read More

CMS Takes Action to Modernize Medicare Home Health

Posted on 11.1.2018

On October 31, CMS finalized significant changes to the Home Health Prospective Payment
System (PPS) to strengthen and modernize Medicare. Specifically, CMS made changes to
improve access to solutions via remote patient monitoring technology, updated payments for
home health care … Read More